ID   K562-mb15
AC   CVCL_C7IL
DR   Wikidata; Q117704568
RX   PubMed=15755898;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 5977; IL15 (membrane bound, contains the signal peptide of CD8A, the mature part of IL15 and the transmembrane domain of CD8A).
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   PubMed=15755898; DOI=10.1182/blood-2004-12-4797;
RA   Imai C., Iwamoto S., Campana D.;
RT   "Genetic modification of primary natural killer cells overcomes
RT   inhibitory signals and induces specific killing of leukemic cells.";
RL   Blood 106:376-383(2005).
//